These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
387 related articles for article (PubMed ID: 33578261)
41. Neuroprotective effects of catechin and quercetin in experimental Parkinsonism through modulation of dopamine metabolism and expression of IL-1β, TNF-α, NF-κB, IκKB, and p53 genes in male Wistar rats. Josiah SS; Famusiwa CD; Crown OO; Lawal AO; Olaleye MT; Akindahunsi AA; Akinmoladun AC Neurotoxicology; 2022 May; 90():158-171. PubMed ID: 35337893 [TBL] [Abstract][Full Text] [Related]
42. Valproic acid is neuroprotective in the rotenone rat model of Parkinson's disease: involvement of alpha-synuclein. Monti B; Gatta V; Piretti F; Raffaelli SS; Virgili M; Contestabile A Neurotox Res; 2010 Feb; 17(2):130-41. PubMed ID: 19626387 [TBL] [Abstract][Full Text] [Related]
44. Potential of the cannabinoid CB(2) receptor as a pharmacological target against inflammation in Parkinson's disease. Gómez-Gálvez Y; Palomo-Garo C; Fernández-Ruiz J; García C Prog Neuropsychopharmacol Biol Psychiatry; 2016 Jan; 64():200-8. PubMed ID: 25863279 [TBL] [Abstract][Full Text] [Related]
45. Neuroprotective and neurorescue effect of black tea extract in 6-hydroxydopamine-lesioned rat model of Parkinson's disease. Chaturvedi RK; Shukla S; Seth K; Chauhan S; Sinha C; Shukla Y; Agrawal AK Neurobiol Dis; 2006 May; 22(2):421-34. PubMed ID: 16480889 [TBL] [Abstract][Full Text] [Related]
46. Protective role of apigenin on rotenone induced rat model of Parkinson's disease: Suppression of neuroinflammation and oxidative stress mediated apoptosis. Anusha C; Sumathi T; Joseph LD Chem Biol Interact; 2017 May; 269():67-79. PubMed ID: 28389404 [TBL] [Abstract][Full Text] [Related]
47. Pharmacological approach using doxycycline and tocopherol in rotenone induced oxidative stress, neuroinflammation and Parkinson's like symptoms. Singh S; Chauhan K Int J Neurosci; 2024 Aug; 134(8):866-881. PubMed ID: 36453937 [TBL] [Abstract][Full Text] [Related]
48. Neuroprotective and Therapeutic Effect of Caffeine on the Rat Model of Parkinson's Disease Induced by Rotenone. Khadrawy YA; Salem AM; El-Shamy KA; Ahmed EK; Fadl NN; Hosny EN J Diet Suppl; 2017 Sep; 14(5):553-572. PubMed ID: 28301304 [TBL] [Abstract][Full Text] [Related]
49. Anti-inflammatory properties rather than anti-oxidant capability is the major mechanism of neuroprotection by sodium salicylate in a chronic rotenone model of Parkinson's disease. Thakur P; Nehru B Neuroscience; 2013 Feb; 231():420-31. PubMed ID: 23159314 [TBL] [Abstract][Full Text] [Related]
50. Anti-inflammatory and neuroprotective activity of boswellic acids in rotenone parkinsonian rats. Ameen AM; Elkazaz AY; Mohammad HMF; Barakat BM Can J Physiol Pharmacol; 2017 Jul; 95(7):819-829. PubMed ID: 28249117 [TBL] [Abstract][Full Text] [Related]
51. N-acetylcysteine prevents rotenone-induced Parkinson's disease in rat: An investigation into the interaction of parkin and Drp1 proteins. Rahimmi A; Khosrobakhsh F; Izadpanah E; Moloudi MR; Hassanzadeh K Brain Res Bull; 2015 Apr; 113():34-40. PubMed ID: 25732239 [TBL] [Abstract][Full Text] [Related]
52. Neuroprotective effect of nerolidol against neuroinflammation and oxidative stress induced by rotenone. Javed H; Azimullah S; Abul Khair SB; Ojha S; Haque ME BMC Neurosci; 2016 Aug; 17(1):58. PubMed ID: 27549180 [TBL] [Abstract][Full Text] [Related]
53. Receptor-heteromer mediated regulation of endocannabinoid signaling in activated microglia. Role of CB Navarro G; Borroto-Escuela D; Angelats E; Etayo Í; Reyes-Resina I; Pulido-Salgado M; Rodríguez-Pérez AI; Canela EI; Saura J; Lanciego JL; Labandeira-García JL; Saura CA; Fuxe K; Franco R Brain Behav Immun; 2018 Jan; 67():139-151. PubMed ID: 28843453 [TBL] [Abstract][Full Text] [Related]
54. Mechanism of toxicity in rotenone models of Parkinson's disease. Sherer TB; Betarbet R; Testa CM; Seo BB; Richardson JR; Kim JH; Miller GW; Yagi T; Matsuno-Yagi A; Greenamyre JT J Neurosci; 2003 Nov; 23(34):10756-64. PubMed ID: 14645467 [TBL] [Abstract][Full Text] [Related]
55. Vanillin Attenuated Behavioural Impairments, Neurochemical Deficts, Oxidative Stress and Apoptosis Against Rotenone Induced Rat Model of Parkinson's Disease. Dhanalakshmi C; Janakiraman U; Manivasagam T; Justin Thenmozhi A; Essa MM; Kalandar A; Khan MA; Guillemin GJ Neurochem Res; 2016 Aug; 41(8):1899-910. PubMed ID: 27038927 [TBL] [Abstract][Full Text] [Related]
56. Sitagliptin and Liraglutide Modulate L-dopa Effect and Attenuate Dyskinetic Movements in Rotenone-Lesioned Rats. Badawi GA; Abd El Fattah MA; Zaki HF; El Sayed MI Neurotox Res; 2019 Apr; 35(3):635-653. PubMed ID: 30673988 [TBL] [Abstract][Full Text] [Related]
57. Fenofibrate promotes neuroprotection in a model of rotenone-induced Parkinson's disease. Barbiero JK; Ramos DC; Boschen S; Bassani T; Da Cunha C; Vital MABF Behav Pharmacol; 2022 Dec; 33(8):513-526. PubMed ID: 36094044 [TBL] [Abstract][Full Text] [Related]
58. Vinpocetine prevents rotenone-induced Parkinson disease motor and non-motor symptoms through attenuation of oxidative stress, neuroinflammation and α-synuclein expressions in rats. Ishola IO; Awogbindin IO; Olubodun-Obadun TG; Olajiga AE; Adeyemi OO Neurotoxicology; 2023 May; 96():37-52. PubMed ID: 36965781 [TBL] [Abstract][Full Text] [Related]
59. Oral Supplements of Mohammed NA; Abdou HM; Tass MA; Alfwuaires M; Abdel-Moneim AM; Essawy AE Curr Pharm Biotechnol; 2020; 21(12):1259-1268. PubMed ID: 32196446 [TBL] [Abstract][Full Text] [Related]
60. Methyl jasmonate ameliorates rotenone-induced motor deficits in rats through its neuroprotective activity and increased expression of tyrosine hydroxylase immunopositive cells. Alabi AO; Ajayi AM; Ben-Azu B; Omorobge O; Umukoro S Metab Brain Dis; 2019 Dec; 34(6):1723-1736. PubMed ID: 31463866 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]